Condition (MeSH)
Hypesthesia
ClinicalTrials.gov lists 44 trials for Hypesthesia or a narrower condition beneath it. Novalar Pharmaceuticals, Inc. has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
44 of the 44 trials are tagged with Hypesthesia itself; the rest are tagged with a narrower condition beneath it.
When did Hypesthesia trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 6 |
| 2024 | 2 |
| 2023 | 4 |
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 1 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 30 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 21 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hypesthesia trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 7 |
| Phase 2/3 | 2 |
| Phase 3 | 3 |
| Phase 4 | 2 |
| Not applicable | 24 |
| Observational | 4 |
How many Hypesthesia trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 8 |
| Completed | 25 |
| Suspended | 1 |
| Terminated | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hypesthesia trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Novalar Pharmaceuticals, Inc. | 4 |
| Columbia Northwest Pharmaceuticals | 1 |
| Combined Military Hospital Kohat Pakistan | 1 |
Which drugs are being tested for Hypesthesia? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Phentolamine | 3 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Radiofrequency ablation alone | 2 |
| Medicinal gas - oxygen (Nippon Gases 200 bar) | 2 |
| Ozone therapy | 2 |
| Cryoablation | 2 |
| 98% dehydrated alcohol | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Hypesthesia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Asthma | 1 | 1 |
| Chest pain | 1 | 1 |
| Cholecystitis | 1 | 1 |
| Drug abuse | 1 | 1 |
| Gastroenteritis | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hypesthesia? (162)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Long-Term Effects of Ozone Treatment in Patients with Persistent Numbness and Tingling Secondary to Chemotherapy-Induced Peripheral Neuropathy. A Retrospective Study. | Integrative cancer therapies | 2025 | Yes |
| Sensorimotor effects of plasticity-inducing percutaneous peripheral nerve stimulation protocols: a blinded, randomized clinical trial. | European journal of pain (London, England) | 2022 | Yes |
| The neurosensory deficit of inferior alveolar nerve following bilateral sagittal split osteotomy: a prospective study. | Oral and maxillofacial surgery | 2022 | Yes |
| Hypoalgesia after exercises with painful vs. non-painful muscles in healthy subjects - a randomized cross-over study. | Scandinavian journal of pain | 2022 | Yes |
| Perineural Platelet-Rich Plasma for Diabetic Neuropathic Pain, Could It Make a Difference? | Pain medicine (Malden, Mass.) | 2020 | Yes |
Showing 5 of 162 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.